uniQure N.V. Other Noncash Income (Expense)
uniQure N.V. (QURE) reported Other Noncash Income (Expense) of $242.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-05-05
- uniQure N.V. other noncash income (expense) for the quarter ending 2026-03-31 was $242.00K, a 93.91% decline year-over-year.
- uniQure N.V. other noncash income (expense) for the quarter ending 2025-12-31 was $2.42M, a 74.06% increase year-over-year.
- uniQure N.V. other noncash income (expense) for the quarter ending 2025-09-30 was -$638.00K, a 115.41% decline year-over-year.
- uniQure N.V. other noncash income (expense) for the quarter ending 2025-06-30 was -$320.00K, a 129.17% decline year-over-year.
- uniQure N.V. other noncash income (expense) for fiscal 2025 was $5.43M, a 41.09% increase from fiscal 2024.
- uniQure N.V. other noncash income (expense) for fiscal 2024 was $3.85M.
- uniQure N.V. other noncash income (expense) for fiscal 2023 was -$4.72M.
- uniQure N.V. other noncash income (expense) for fiscal 2022 was -$1.60M, a 157.32% decline from fiscal 2021.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 3 month as first filed | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 6 month as first filed | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 12 month |
|---|---|---|---|---|---|---|
| 2026-03-31 | $242.00K 10-Q · filed 2026-05-05 | $2.66M derived: sum of 2 quarters · filed 2026-05-05 | $2.02M derived: sum of 3 quarters · filed 2026-05-05 | $1.70M derived: sum of 4 quarters · filed 2026-05-05 | ||
| 2025-12-31 | $2.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.78M derived: sum of 2 quarters · filed 2026-03-02 | $1.46M derived: sum of 3 quarters · filed 2026-03-02 | $5.43M 10-K · filed 2026-03-02 | ||
| 2025-09-30 | -$638.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$958.00K derived: sum of 2 quarters · filed 2025-11-10 | $3.01M 10-Q · filed 2025-11-10 | $4.40M derived: sum of 4 quarters · filed 2026-05-05 | ||
| 2025-06-30 | -$320.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | $3.65M 10-Q · filed 2025-07-29 | $5.04M derived: sum of 3 quarters · filed 2026-05-05 | $9.18M derived: sum of 4 quarters · filed 2026-05-05 | ||
| 2025-03-31 | $3.97M 10-Q · filed 2026-05-05 | $5.36M derived: sum of 2 quarters · filed 2026-05-05 | $9.50M derived: sum of 3 quarters · filed 2026-05-05 | $10.60M derived: sum of 4 quarters · filed 2026-05-05 | ||
| 2024-12-31 | $1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $5.53M derived: sum of 2 quarters · filed 2026-03-02 | $6.63M derived: sum of 3 quarters · filed 2026-03-02 | $3.85M 10-K · filed 2026-03-02 | ||
| 2024-09-30 | $4.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $5.24M derived: sum of 2 quarters · filed 2025-11-10 | $2.46M 10-Q · filed 2025-11-10 | -$115.00K derived: sum of 4 quarters · filed 2026-03-02 | ||
| 2024-06-30 | $1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | -$1.68M 10-Q · filed 2025-07-29 | -$4.26M derived: sum of 3 quarters · filed 2026-03-02 | -$5.40M derived: sum of 4 quarters · filed 2026-03-02 | ||
| 2024-03-31 | -$2.78M 10-Q · filed 2025-05-09 | -$5.35M derived: sum of 2 quarters · filed 2026-03-02 | -$6.49M derived: sum of 3 quarters · filed 2026-03-02 | -$7.04M derived: sum of 4 quarters · filed 2026-03-02 | ||
| 2023-12-31 | -$2.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$3.71M derived: sum of 2 quarters · filed 2026-03-02 | -$4.26M derived: sum of 3 quarters · filed 2026-03-02 | -$4.72M 10-K · filed 2026-03-02 | ||
| 2023-09-30 | -$1.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$1.69M derived: sum of 2 quarters · filed 2024-11-05 | -$2.15M 10-Q · filed 2024-11-05 | -$4.33M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-06-30 | -$550.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$1.01M 10-Q · filed 2024-08-01 | $831.00K 10-Q · filed 2023-08-01 | -$3.19M derived: sum of 3 quarters · filed 2025-02-27 | -$2.87M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | -$456.00K 10-Q · filed 2024-05-07 | $469.00K 10-Q · filed 2023-05-09 | -$2.64M derived: sum of 2 quarters · filed 2025-02-27 | -$2.32M derived: sum of 3 quarters · filed 2025-02-27 | ||
| 2022-12-31 | -$2.19M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$1.86M derived: sum of 2 quarters · filed 2025-02-27 | -$1.60M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $324.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $581.00K 10-Q · filed 2023-11-07 | ||||
| 2022-06-30 | $257.00K 10-Q · filed 2023-08-01 | |||||
| 2021-12-31 | -$62.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$132.00K derived: sum of 2 quarters · filed 2024-02-28 | $2.80M 10-K · filed 2024-02-28 | |||
| 2021-09-30 | -$70.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-25 | $2.86M 10-Q · filed 2021-10-25 | ||||
| 2021-06-30 | $2.93M 10-Q · filed 2022-08-08 | -$539.00K 10-Q · filed 2021-07-26 | ||||
| 2020-09-30 | $482.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-25 | $2.08M 10-Q · filed 2021-10-25 | ||||
| 2020-06-30 | $1.60M 10-Q · filed 2021-07-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |